Stocks to Watch: Oracle, MGM, Meta -- WSJ
Dow Jones2026/09/24 14:13By WSJ Staff
Oracle (ORCL): Shares in the tech company slumped after Bloomberg reported that it had invoked force majeure to shield itself from payments on a data center project. According to the report, the project's developer is a unit of Blue Owl Capital (OWL), whose shares also fell.
MGM Resorts (MGM): Shares slid after Barry Diller said he was withdrawing his bid for the casino operator.
Meta Platforms (META): The tech giant's shares rose after it announced new pairs of smart glasses and a hand-held device that would integrate its recently launched Muse AI agent. The stock is up more than 14% this week.
National Stock Exchange of India (IN:544937): The stock rose as much as 5.2% in its long-awaited stock-market debut in Mumbai.
Costco Wholesale (COST): The company is due to report earnings after the closing bell.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
September 24, 2026 10:13 ET (14:13 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
